+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncolytic Virus Therapies Market - Global Forecast 2026-2032- Product Image
Oncolytic Virus Therapies Market - Global Forecast 2026-2032- Product Image
New

Oncolytic Virus Therapies Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5925124
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncolytic virus therapies market is undergoing significant transformation, driven by scientific advancements and strategic shifts in operational models. Senior stakeholders require focused, actionable insights to address evolving clinical and commercial dynamics and maintain strategic decision-making advantages in this specialized sector.

Market Snapshot: Growth and Opportunity in Oncolytic Virus Therapies

The Oncolytic Virus Therapies Market expanded from USD 153.79 million in 2025 to USD 184.98 million in 2026, with a compound annual growth rate (CAGR) of 16.38%. This strong growth trajectory is expected to propel the market toward USD 444.83 million by 2032. Expansion is being fueled by widened clinical applications, new research investment, and increasing integration of these therapies in the broader oncology market, as both established healthcare institutions and innovators build capabilities throughout the value chain.

Scope & Segmentation: Technology and Geographies Shaping Market Focus

  • Cancer Indications: Glioblastoma, Head and Neck Cancer, Melanoma—all require distinct clinical and operational solutions, from complex delivery strategies in brain cancers to disease control in metastatic melanoma.
  • Virus Types: Genetically Modified Viruses, including Adenovirus, Herpes Simplex Virus, Vaccinia Virus, alongside Wild Type Virus. Each virus platform presents different immunogenic profiles, payload capacities, and production requirements, influencing development timelines and deployment logistics.
  • Administration Routes: Intratumoral and Intravenous approaches influence patient eligibility, safety oversight, and systemic distribution. Each method affects trial design, patient monitoring, and logistics for therapy supply.
  • End Users: Hospitals, Research Institutes, Specialty Clinics. Operational infrastructure, clinical integration, and opportunities for collaborative research differ across these user settings, shaping adoption speed and patient access.
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific. Regional strengths and constraints impact research intensity, regulatory pathways, compliance standards, and the overall pace of clinical adoption in each area.

Key Takeaways for Stakeholders in Oncolytic Virus Therapy

  • Oncolytic virus therapies offer dual clinical value by promoting targeted destruction of tumor cells and enhancing immune response, supporting their consideration in combination oncology regimens.
  • Advances in vector and payload engineering are enabling improved tumor targeting and flexibility, unlocking the potential for use across a broader spectrum of cancer types.
  • Regulatory agencies are moving to incorporate translational biomarkers and long-term data into evaluation criteria, which is anticipated to streamline the development timeline for complex biologics.
  • Strategic partnerships between academia and industry are proving essential in facilitating the transition from preclinical innovation to late-stage commercialization, combining risk-sharing and specialist know-how.
  • Adaptive or platform-based clinical trial models are increasingly being utilized to evaluate therapies across multiple cancer indications, supporting optimal resource deployment and faster evidence generation.

Tariff Impact: Navigating Cost and Supply Chain Challenges

Recent United States tariff policy changes have introduced greater cost management and supply continuity challenges for oncolytic virus therapy producers. In response, organizations are reassessing supplier agreements and increasing diversification to minimize the impact of higher import duties on both raw materials and finished therapies. Establishing regional production hubs and forming flexible partnerships can build resilience, while well-defined contracts and regular engagement with regulatory authorities help secure clinical and commercial supply chains amid evolving trade dynamics.

Methodology & Data Sources

This market analysis is informed by in-depth interviews with experts in clinical development, manufacturing, and commercialization, supplemented by peer-reviewed literature and regulatory intelligence. A combination of qualitative triangulation and scenario mapping was used to validate findings and anticipate sector-wide operational risks.

Why This Report Matters

  • Enables senior leaders to make informed decisions through clarity on clinical, operational, and strategic trends driving the oncolytic virus therapies market.
  • Provides actionable frameworks to address manufacturing, distribution, and regulatory complexities with a global and region-specific context.
  • Prepares organizations to enhance product development efficiency, fortify supply chains, and broaden access to advanced oncology solutions.

Conclusion

The oncolytic virus therapies sector’s evolution is being shaped by rapid innovation, resilient operations, and collaborative industry-academic models. Ongoing alignment across technology, supply chain, and regulatory strategies will be central to achieving sustainable clinical and commercial progress.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Oncolytic Virus Therapies Market, by Virus Type
8.1. Genetically Modified Virus
8.1.1. Adenovirus
8.1.2. Herpes Simplex Virus
8.1.3. Vaccinia Virus
8.2. Wild Type Virus
9. Oncolytic Virus Therapies Market, by Cancer Indication
9.1. Glioblastoma
9.2. Head And Neck Cancer
9.3. Melanoma
10. Oncolytic Virus Therapies Market, by Administration Route
10.1. Intratumoral
10.2. Intravenous
11. Oncolytic Virus Therapies Market, by End User
11.1. Hospitals
11.2. Research Institutes
11.3. Specialty Clinics
12. Oncolytic Virus Therapies Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Oncolytic Virus Therapies Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Oncolytic Virus Therapies Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Oncolytic Virus Therapies Market
16. China Oncolytic Virus Therapies Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Amunbio Inc.
17.6. Astellas Pharma Inc.
17.7. AstraZeneca PLC
17.8. BioInvent International AB
17.9. Boehringer Ingelheim International GmbH
17.10. Calidi Biotherapeutics, Inc.
17.11. Candel Therapeutics
17.12. Daiichi Sankyo Company Ltd.
17.13. Elicera Therapeutics AB
17.14. EpicentRx, Inc.
17.15. Genelux Corporation
17.16. Hookipa Pharma Inc.
17.17. Imvaq Therapeutics
17.18. Istari Oncology, Inc.
17.19. Johnson & Johnson Services, Inc.
17.20. Lokon Pharma AB
17.21. Merck & Co., Inc.
17.22. Orgenesis Inc.
17.23. Pfizer, Inc.
17.24. Protheragen Inc.
17.25. Seneca Therapeutics, Inc.
17.26. Takara Bio Inc.
17.27. TILT Biotherapeutics
17.28. Treovir LLC
17.29. Wuhan Binhui Biotechnology Co Ltd
List of Figures
FIGURE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 48. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 49. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 53. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 55. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 59. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 61. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 73. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 74. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 75. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 76. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 79. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 85. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 86. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 87. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 88. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 98. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 99. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 100. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 101. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 104. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 105. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 106. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 107. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 116. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 117. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 118. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 119. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 122. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 123. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 124. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 125. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 128. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 129. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 130. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 131. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 134. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 135. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 140. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
TABLE 141. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
TABLE 142. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
TABLE 143. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 144. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Oncolytic Virus Therapies market report include:
  • Amunbio Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Calidi Biotherapeutics, Inc.
  • Candel Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Elicera Therapeutics AB
  • EpicentRx, Inc.
  • Genelux Corporation
  • Hookipa Pharma Inc.
  • Imvaq Therapeutics
  • Istari Oncology, Inc.
  • Johnson & Johnson Services, Inc.
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Orgenesis Inc.
  • Pfizer, Inc.
  • Protheragen Inc.
  • Seneca Therapeutics, Inc.
  • Takara Bio Inc.
  • TILT Biotherapeutics
  • Treovir LLC
  • Wuhan Binhui Biotechnology Co Ltd

Related Topics

Related Reports

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Oncolytic Virus Immunotherapy Market - Global Strategic Business Report - Product Image

Oncolytic Virus Immunotherapy Market - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Oncolytic Virotherapy Market - Global Strategic Business Report - Product Image

Oncolytic Virotherapy Market - Global Strategic Business Report

  • Report
  • 243 Pages
  • Global
From

About the Market

The Oncolytic Virus Drug market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Oncolytic virus drugs are a type of biologic therapy that uses viruses to target and destroy cancer cells. These drugs are designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. They can be used alone or in combination with other treatments such as chemotherapy or radiation therapy. Oncolytic virus drugs have the potential to improve the efficacy of existing treatments and reduce the side effects associated with them. Some companies in the Oncolytic Virus Drug market include Amgen, Merck, Pfizer, and Novartis. These companies are actively researching and developing new oncolytic virus drugs to treat a variety of cancers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.